Bhattacharyya Chandrika, Majumder Partha Pratim, Pandit Bhaswati
National Institute of Biomedical Genomics, PO: NSS, Kalyani, West Bengal 741251, India.
Tuberculosis (Edinb). 2018 Mar;109:8-16. doi: 10.1016/j.tube.2018.01.005. Epub 2018 Feb 2.
Variability in clinical outcome of tuberculosis infection is dependent, among other factors, on variation in host immunological response to the infection, which is modulated, in part by genetic variations present in the host. We undertook a study to identify host factors associated with such clinical variability.
A comparative study between groups of active TB patients vs. clinically normal household contacts, family members living under the same roof with the patients for a long period of time, was carried out. We screened 22 candidate cytokines and chemokines in the plasma of 119 pairs ("discovery set") of TB patients and their asymptomatic household contacts. Identified associations were validated in an independent cohort of 78 patient-household contact pairs ("validation set"). Validated associations were further cross-validated by gene expression assays using RT-PCR and in-vitro whole blood stimulation by mycobacterial antigens ESAT6 and Rv2031c, two well-characterized antigens that are expressed in active and latent phases of disease, respectively. In a concomitant SNP association study, we have sequenced the validated gene in these patients and household contacts.
CXCL10 was found to be the most significantly (p = 0.0002) elevated chemokine - discovered and validated -- in patients' plasma compared to their household contacts. We found that CXCL10 was overexpressed by 5-fold at the RNA level in patients compared to asymptomatic household contacts (p = 0.004). On stimulation of whole blood collected from normal healthy volunteers with mycobacterial antigens ESAT6 and Rv2031c, we found that production of CXCL10 by ESAT6 was significantly higher (p = 2.8 × 10) than Rv2031c. The production of CXCL10 was 20-fold more than IFN-γ, the most widely validated cytokine, by ESAT6 stimulation (p = 4.6 × 10). One of the polymorphisms in promoter of CXCL10, rs4508917 (-1447 A > G), was identified as a proteinQTL (pQTL). Reduced expression of CXCL10 was observed among individuals with GG genotype, but the reduction was statistically significant only among controls, but not among patients. Among patients, the expression level was very high compared to the controls irrespective of the genotypes at this locus.
Plasma level of CXCL10 is predictive of the active phase of TB infection.
结核病感染临床结果的变异性取决于多种因素,其中包括宿主对感染的免疫反应差异,而这种差异部分受宿主存在的基因变异调节。我们开展了一项研究以确定与这种临床变异性相关的宿主因素。
对活动性肺结核患者组与临床正常的家庭接触者(与患者长期同住一个屋檐下的家庭成员)进行了一项对比研究。我们在119对(“发现集”)肺结核患者及其无症状家庭接触者的血浆中筛选了22种候选细胞因子和趋化因子。在一个由78对患者 - 家庭接触者组成的独立队列(“验证集”)中对确定的关联进行验证。通过使用逆转录 - 聚合酶链反应(RT - PCR)的基因表达测定以及用结核分枝杆菌抗原ESAT6和Rv2031c进行体外全血刺激对验证的关联进行进一步交叉验证,ESAT6和Rv2031c是两种特征明确的抗原,分别在疾病的活动期和潜伏期表达。在一项伴随的单核苷酸多态性(SNP)关联研究中,我们对这些患者和家庭接触者中的验证基因进行了测序。
与家庭接触者相比,发现CXCL10是患者血浆中升高最显著(p = 0.0002)的趋化因子——已发现并验证。我们发现与无症状家庭接触者相比,患者在RNA水平上CXCL10的表达量高5倍(p = 0.004)。在用结核分枝杆菌抗原ESAT6和Rv2031c刺激从正常健康志愿者采集的全血时,我们发现ESAT6刺激产生的CXCL10显著高于Rv2031c(p = 2.8×10)。ESAT6刺激产生的CXCL10比最广泛验证的细胞因子干扰素 - γ多20倍(p = 4.6×10)。CXCL10启动子中的一个多态性,rs4508917( - 1447 A>G),被鉴定为蛋白质定量性状位点(pQTL)。在GG基因型个体中观察到CXCL10表达降低,但仅在对照组中降低具有统计学意义,而在患者中没有。在患者中,无论该位点的基因型如何,其表达水平与对照组相比都非常高。
CXCL10的血浆水平可预测结核病感染的活动期。